Adam covers proteomics and life science mass spectrometry for GenomeWeb.
The company said in April that it planned to launch a test this year but has since decided to take more time to better assess the clinical need and market.
The work demonstrates the ability of mass spectrometry to profile protein complexes in their native states in great detail and with relatively high throughput.
The approach combines a mutant tRNA synthetase and cell-specific promoters to label proteins with molecules that can then be pulled down via click-chemistry.
The method from University of Texas researchers combines carbamylation of proteins prior to trypsin digestion with ultraviolet photodissociation mass spec.
The company believes the approach could allow researchers to profile tumor signaling pathways via blood or urine samples, similar to how ctDNA analysis is used.
The firm is using a $1.8 million SBIR grant and $13.5 million Series B round to automate its single-cell analysis tech for clinical trials in T cell therapies.
The system can measure dozens of markers at the single-cell level and, one researcher said, could aid studies of cellular heterogeneity in diseases like cancer.
The approach could enable more mass spec-friendly workflows and better identification and localization of biotinylation sites.
According to the researchers, the system combines the qualities of conventional small molecule probes and cross-reactive sensor arrays like chemical "noses."
The researchers established the suitability of FraC nanopores for protein analysis and offered a new approach to driving proteins into nanopores for detection.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.